Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.
PURPOSE: To explore the effects of Icaritin on chronic myeloid leukemia (CML) cells and underlying mechanisms. METHOD: CML cells were incubated with various concentration of Icaritin for 48 hours, the cell proliferation was analyzed by MTT and the apoptosis was assessed with Annexin V and Hoechst 33...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3161749?pdf=render |
id |
doaj-c1379323f5474812810626a101d8e99e |
---|---|
record_format |
Article |
spelling |
doaj-c1379323f5474812810626a101d8e99e2020-11-25T02:27:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0168e2372010.1371/journal.pone.0023720Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.Jian feng ZhuZi jian LiGuang sen ZhangKun MengWen yong KuangJin LiXin fu ZhouRui juan LiHong ling PengChong wen DaiJian Kai ShenFan jie GongYun xiao XuSu fang LiuPURPOSE: To explore the effects of Icaritin on chronic myeloid leukemia (CML) cells and underlying mechanisms. METHOD: CML cells were incubated with various concentration of Icaritin for 48 hours, the cell proliferation was analyzed by MTT and the apoptosis was assessed with Annexin V and Hoechst 33258 staining. Cell hemoglobinization was determined. Western blotting was used to evaluate the expressions of MAPK/ERK/JNK signal pathway and Jak-2/Phorpho-Stat3/Phorsph-Akt network-related protein. NOD-SCID nude mice were applied to demonstrate the anti-leukemia effect of Icaritin in vivo. RESULTS: Icaritin potently inhibited proliferation of K562 cells (IC50 was 8 µM) and primary CML cells (IC50 was 13.4 µM for CML-CP and 18 µM for CML-BC), induced CML cells apoptosis and promoted the erythroid differentiation of K562 cells with time-dependent manner. Furthermore, Icaritin was able to suppress the growth of primary CD34+ leukemia cells (CML) and Imatinib-resistant cells, and to induce apoptosis. In mouse leukemia model, Icaritin could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells as effective as Imatinib without suppression of bone marrow. Icaritin could up-regulate phospho-JNK or phospho-C-Jun and down-regulate phospho-ERK, phospho-P-38, Jak-2, phospho-Stat3 and phospho-Akt expression with dose- or time-dependent manner. Icaritin had no influence both on c-Abl and phospho-c-Abl protein expression and mRNA levels of Bcr/Abl. CONCLUSION: Icaritin from Chinese herb medicine may be a potential anti-CML agent with low adverse effect. The mechanism of anti-leukemia for Icaritin is involved in the regulation of Bcr/Abl downstream signaling. Icaritin may be useful for an alternative therapeutic choice of Imatinib-resistant forms of CML.http://europepmc.org/articles/PMC3161749?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jian feng Zhu Zi jian Li Guang sen Zhang Kun Meng Wen yong Kuang Jin Li Xin fu Zhou Rui juan Li Hong ling Peng Chong wen Dai Jian Kai Shen Fan jie Gong Yun xiao Xu Su fang Liu |
spellingShingle |
Jian feng Zhu Zi jian Li Guang sen Zhang Kun Meng Wen yong Kuang Jin Li Xin fu Zhou Rui juan Li Hong ling Peng Chong wen Dai Jian Kai Shen Fan jie Gong Yun xiao Xu Su fang Liu Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS ONE |
author_facet |
Jian feng Zhu Zi jian Li Guang sen Zhang Kun Meng Wen yong Kuang Jin Li Xin fu Zhou Rui juan Li Hong ling Peng Chong wen Dai Jian Kai Shen Fan jie Gong Yun xiao Xu Su fang Liu |
author_sort |
Jian feng Zhu |
title |
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. |
title_short |
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. |
title_full |
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. |
title_fullStr |
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. |
title_full_unstemmed |
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. |
title_sort |
icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating mapk/erk/jnk and jak2/stat3 /akt signalings. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
PURPOSE: To explore the effects of Icaritin on chronic myeloid leukemia (CML) cells and underlying mechanisms. METHOD: CML cells were incubated with various concentration of Icaritin for 48 hours, the cell proliferation was analyzed by MTT and the apoptosis was assessed with Annexin V and Hoechst 33258 staining. Cell hemoglobinization was determined. Western blotting was used to evaluate the expressions of MAPK/ERK/JNK signal pathway and Jak-2/Phorpho-Stat3/Phorsph-Akt network-related protein. NOD-SCID nude mice were applied to demonstrate the anti-leukemia effect of Icaritin in vivo. RESULTS: Icaritin potently inhibited proliferation of K562 cells (IC50 was 8 µM) and primary CML cells (IC50 was 13.4 µM for CML-CP and 18 µM for CML-BC), induced CML cells apoptosis and promoted the erythroid differentiation of K562 cells with time-dependent manner. Furthermore, Icaritin was able to suppress the growth of primary CD34+ leukemia cells (CML) and Imatinib-resistant cells, and to induce apoptosis. In mouse leukemia model, Icaritin could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells as effective as Imatinib without suppression of bone marrow. Icaritin could up-regulate phospho-JNK or phospho-C-Jun and down-regulate phospho-ERK, phospho-P-38, Jak-2, phospho-Stat3 and phospho-Akt expression with dose- or time-dependent manner. Icaritin had no influence both on c-Abl and phospho-c-Abl protein expression and mRNA levels of Bcr/Abl. CONCLUSION: Icaritin from Chinese herb medicine may be a potential anti-CML agent with low adverse effect. The mechanism of anti-leukemia for Icaritin is involved in the regulation of Bcr/Abl downstream signaling. Icaritin may be useful for an alternative therapeutic choice of Imatinib-resistant forms of CML. |
url |
http://europepmc.org/articles/PMC3161749?pdf=render |
work_keys_str_mv |
AT jianfengzhu icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT zijianli icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT guangsenzhang icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT kunmeng icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT wenyongkuang icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT jinli icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT xinfuzhou icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT ruijuanli icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT honglingpeng icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT chongwendai icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT jiankaishen icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT fanjiegong icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT yunxiaoxu icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings AT sufangliu icaritinshowspotentantileukemiaactivityonchronicmyeloidleukemiainvitroandinvivobyregulatingmapkerkjnkandjak2stat3aktsignalings |
_version_ |
1724841759233540096 |